Scientific articleDurability of Collagenase Treatment for Dupuytren Disease of the Thumb and First Web After at Least 2 Years’ Follow-Up
Section snippets
Material and Methods
All 12 patients with 14 hands who previously participated in the efficacy study of CCH in thumb and first web contractures13 were approached an average of 35 months (range, 24–40 months) after their initial CCH treatment and asked to participate in this follow-up study. The local Medical Ethics Committee approved the study. The study was conducted according to the principles of the Declaration of Helsinki and in accordance with the Medical Research Involving Human Subjects Act (Wet Mensgebonden
Results
Eleven patients with DD on the radial side of their hands were available for this follow-up study (11 out of 12 patients). The included patients had a mean age of 64 years (± SD, 4.4) and 8 of them were men. Eight out of the 11 patients were treated in the left hand. All patients had the disease in both hands and all hands except 1 had been treated previously for DD located elsewhere in the hand, reflecting the severity of the disease in these patients. In addition, 5 patients also had
Discussion
In this follow-up study, we found that the effect of the treatment with CCH in first web contractures (IMDs) continued to be stable in most cases at a mean follow-up of 35 months after treatment. However, overall, we saw a deterioration of PED at MCP joints and IP joints, with a better durability for MCP joints than for IP joints. Notwithstanding this, 5 out of 11 patients (1 at the treated MCP joint, 3 at the treated IP joints, and 1 at the treated first web) met the definition of recurrence
Acknowledgment
We thank D. Broekstra MSc, PhD, who trained the investigator to properly use the goniometer to maximize interobserver agreement. Furthermore, we thank her for assisting with statistical analysis.
References (26)
Dupuytren's disease affecting the thumb and first web of the hand
J Hand Surg Br
(2003)Dupuytren's disease of the radial side of the hand
Hand Clin
(1999)- et al.
Enzyme injection as nonsurgical treatment of Dupuytren's disease
J Hand Surg Am
(2000) - et al.
Collagen as a clinical target: nonoperative treatment of Dupuytren's disease
J Hand Surg Am
(2002) - et al.
Efficacy and safety of injectable mixed collagenase subtypes in the treatment of Dupuytren’s contracture
J Hand Surg Am
(2007) On the origin and spread of Dupuytren's disease
J Hand Surg Am
(2002)- et al.
The impact of collagenase Clostridium histolyticum introduction on Dupuytren treatment patterns in the United States
J Hand Surg Am
(2016) - et al.
Collagenase treatment for Dupuytren disease of the thumb and first web
J Hand Surg Am
(2016) Intra- and inter-observer agreement on diagnosis of Dupuytren disease, measurements of severity of contracture, and disease extent
Man Ther
(2015)- et al.
Dupuytren's contracture: an audit of the outcomes of surgery
J Hand Surg Br
(2006)
Steroid injection and needle aponeurotomy for Dupuytren contracture: a randomized, controlled study
J Hand Surg Am
Patterns of recontracture after surgical correction of Dupuytren disease
J Hand Surg Am
Dupuytren contracture recurrence following treatment with collagenase Clostridium histolyticum (CORDLESS study): 3-year data
J Hand Surg Am
Cited by (2)
Dupuytren Contractures: An Update of Recent Literature
2021, Journal of Hand SurgeryCitation Excerpt :A recent study demonstrated that practitioners may administer the full content of the vial, as much as 0.8 mg per vial or a total of 1.6 mg for multiple digits, in a single visit without a significant increase in severe complications.24 Recent studies have also demonstrated the safety and efficacy of CCH when used to treat retrovascular cords, cords involving the thumb and first webspace, and recurrent disease.27–31 Rates of initial correction following collagenase are similar to those following NA.
Dupuytren’s disease of the thumb and first web space: treatment strategy
2023, Minerva Orthopedics
During the course of the study, P.M.N.W was a member of the advisory boards of Pfizer Lts and Sobi Ltd. At present he is on the scientific advisory board of Fidia Pharma (Milan, Italy). The Department of Plastic Surgery at University Medical Centre Groningen receives his honorarium, which is used for research purposes and he is reimbursed for his travel costs. The rest of the authors declare that they have no relevant conflicts of interest.